Skip to content
Screener

G&A at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$15.59M+9.2%
LON
LeonaBio, Inc.LONA
$6.88M+31.5%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$21.13M+19.7%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$10.13M+25.2%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$11.37M+81.5%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$8.49M+54.9%

Segments

By segment

See full
Reportable Segment$19.1M-28.2%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$572.13M+18.3%
Enterprise value$493.43M+30.3%
P/S6.4×+5.1×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Arvinas’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 5:18 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033669
(dollars and shares in millions, except per share amounts) / Consolidated Statements of OperationsFor the Three Months Ended March 31, 2026For the Three Months Ended March 31, 2025
Revenue$15.6$188.8
Operating expenses:
Research and development60.390.8
General and administrative19.126.6
Total operating expenses79.4117.4
(Loss) income from operations(63.8)71.4
Other income
Other expense, net(0.1)

Item 1. Financial Statements (Unaudited)

FAQ

What is Arvinas's G&A?
Arvinas (ARVN) reported G&A of $19.1M in Q1 2026.
How has Arvinas's G&A changed year-over-year?
Arvinas's G&A decreased by 28.2% year-over-year, from $26.6M to $19.1M.
What is the long-term trend for Arvinas's G&A?
Over 4 years (2021 to 2025), Arvinas's G&A has grown at a 11.7% compound annual growth rate (CAGR), from $61.5M to $95.9M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ask your AI about Arvinas's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude